Observational analysis
Study theme · illustration
Read the results alongside the study design, safety findings and limitations.

Who was studied?

203 patients from PRaG studies: 165 for biomarker discovery/model construction and another 38 for independent internal validation.

What does the publication report?

The model incorporating detailed T-cell subsets achieved AUC 0.913 in the 38-patient internal validation cohort. This is a prediction study, not a new efficacy trial.

Safety findings

In the 165-patient discovery cohort, 71 (43.0%) had grade ≥2 AEs, including 12 (7.3%) with grade ≥3 AEs; these percentages do not use 203 as denominator.

How should we interpret it?

Internal validation does not establish external clinical utility. Pooled patients may overlap with other PRaG publications.

Read the original source

This independently written summary was checked against the original full publication. It is an educational summary, not a full-paper translation or clinical recommendation.

Dynamic circulating biomarkers for predicting adverse events in PRaG therapy: a pooled analysis and model construction from PRaG series clinical trials · DOI: 10.1007/s00262-025-04292-w · PMID: 41591538

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.